Disease · MONDO_0003529

acute pyelonephritis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. acute pyelonephritis. Diseases, record MONDO_0003529. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003529

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: acute pyelonephritis; Open Targets
Open Targets ID: MONDO_0003529; Open Targets
Other names: pyelonephritis, acute; Open Targets
Disease Ontology: DOID:559; Disease Ontology
NCI Thesaurus: C123215; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 29 of its 39 drugs, from ClinicalTrials.gov; Open Targets

Drugs39

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MEROPENEM	CHEMBL127	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
CEFEPIME	CHEMBL186	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
LEVOFLOXACIN	CHEMBL5315124	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
AVIBACTAM	CHEMBL1689063	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
CEFTAZIDIME	CHEMBL44354	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
ERTAPENEM	CHEMBL1359	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
PLAZOMICIN	CHEMBL1650559	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
CEFTRIAXONE	CHEMBL161	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CILASTATIN	CHEMBL766	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ENMETAZOBACTAM	CHEMBL4458276	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 39

See all 39 drugs

Targets2

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DPEP1	Dipeptidase 1	1	Renal dipeptidase inhibitor	Phase 3	https://conductscience.org/library/genes/1800	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets

Trials32

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT06059846	A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)	Phase 3	1,690	2026-03-10	Urinary Tract Infection, Acute Pyelonephritis	TEBIPENEM PIVOXIL HYDROBROMIDE	Its record names the disease	ClinicalTrials.gov
NCT03788967	Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)	Phase 3	1,372	2022-07-25	Complicated Urinary Tract Infection, Acute Pyelonephritis	ERTAPENEM, TEBIPENEM PIVOXIL HYDROBROMIDE	Its record names the disease	ClinicalTrials.gov
NCT03840148	Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections	Phase 3	661	2024-05-29	Urinary Tract Infections, Acute Pyelonephritis	CEFEPIME, MEROPENEM, TANIBORBACTAM	Its record names the disease	ClinicalTrials.gov
NCT01599806	Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)	Phase 3	641	2016-03-02	Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis	AVIBACTAM, CEFTAZIDIME	Its record names the disease	ClinicalTrials.gov
NCT02486627	A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)	Phase 3	609	2018-08-23	Complicated Urinary Tract Infection, Acute Pyelonephritis	MEROPENEM, PLAZOMICIN	Its record names the disease	ClinicalTrials.gov
NCT01595438	Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)	Phase 3	598	2016-03-09	Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis	AVIBACTAM, CEFTAZIDIME, DORIPENEM	Its record names the disease	ClinicalTrials.gov
NCT02166476	Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP	Phase 3	550	2017-10-26	Urinary Tract Infection Complicated, Acute Pyelonephritis	LEVOFLOXACIN, MEROPENEM	Its record names the disease	ClinicalTrials.gov
NCT02753946	Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections	Phase 2/3	465	2018-12-11	Urinary Tract Infection Symptomatic, Acute Pyelonephritis, Urinary Tract Infection Complicated	FOSFOMYCIN, PIPERACILLIN	Its record names the disease	ClinicalTrials.gov
NCT01014013	Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)	Phase 3	271	2010-03-01	Urinary Tract Infection	ERTAPENEM SODIUM	Its record names the disease	ClinicalTrials.gov
NCT01928433	Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis	Phase 2	225	2017-06-20	Urinary Tract Infections, Acute Pyelonephritis	FINAFLOXACIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 32

See all 32 trials

Comparisons in its trials89

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
TBP-PI-HBr vs Imipenem-cilastatin: deaths from any cause	2 of 843	2 of 844	1,687	NCT06059846	Trial comparisons
TBP-PI-HBr vs Imipenem-cilastatin: serious adverse events	29 of 843	22 of 844	1,687	NCT06059846	Trial comparisons
TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in The Safety Population	176 of 685	176 of 687	1,372	NCT03788967	Trial comparisons
TBPM-PI-HBr 600 mg vs Ertapenem 1 g: deaths from any cause	0 of 685	0 of 687	1,372	NCT03788967	Trial comparisons
TBPM-PI-HBr 600 mg vs Ertapenem 1 g: serious adverse events	14 of 685	12 of 687	1,372	NCT03788967	Trial comparisons
TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Clinical Cure at EOT Days the Clinically Evaluable (CE-EOT) Populations	673 of 677	665 of 674	1,351	NCT03788967	Trial comparisons
TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Clinical Cure at TOC in the CE-TOC Populations	611 of 641	617 of 637	1,278	NCT03788967	Trial comparisons
TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Sustained Clinical Cure at LFU in the CE-LFU Populations	556 of 596	559 of 596	1,192	NCT03788967	Trial comparisons
CAZ-AVI vs Doripenem: serious adverse events	21 of 511	12 of 509	1,020	NCT01595438	Trial comparisons
CAZ-AVI vs Doripenem: serious adverse events	21 of 511	12 of 509	1,020	NCT01599806	Trial comparisons

1 to 10 of 89

See all 89 comparisons in its trials

Papers from its trials33

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31433059	RESULT	1	PubMed
22563210	RESULT	1	PubMed
18242357	RESULT	1	PubMed
18042477	RESULT	1	PubMed
17880755	RESULT	1	PubMed
41949135	DERIVED	1	PubMed
40827922	DERIVED	1	PubMed
38780262	DERIVED	1	PubMed
38354140	DERIVED	1	PubMed
37700689	DERIVED	1	PubMed

1 to 10 of 33

See all 33 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0003529

GET https://conductscience.org/api/diseases/v1/MONDO_0003529/drugs?page=2

API reference For AI assistants